SCHEMBL6968614

SCHEMBL6968614

Cc1cc(C2CCN(S(=O)(=O)C3(C(=O)O)CCN(C)CC3)CC2)ccc1-c1cccc(OCCO)n1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.64
MMP3 P08254 7/20 0.64
MMP1 P03956 2/20 0.64
MMP9 P14780 2/20 0.64
MMP14 P50281 2/20 0.64
FFAR4 Q5NUL3 3/20 0.33
JAK2 O60674 1/20 0.32
CYP3A4 P08684 1/20 0.32
JAK1 P23458 1/20 0.32
JAK3 P52333 1/20 0.32
PTK2 Q05397 1/20 0.32
GUCY1A1 Q02108 5/20 0.32
GUCY1B1 Q02153 5/20 0.32
HSD11B1 P28845 1/20 0.32
ENPP2 Q13822 1/20 0.32
HTR1A P08908 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
MCHR1 Q99705 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6434330 0.93 MMP2 (0.63) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971907 0.92 MMP2 (0.65) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6956221 0.92 MMP2 (0.68) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6968340 0.92 MMP2 (0.63) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6435284 0.92 MMP2 (0.63) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6437634 0.89 MMP2 (0.63) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6959958 0.88 MMP2 (0.60) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433718 0.85 MMP2 (0.62) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6439579 0.85 MMP2 (0.62) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433723 0.84 MMP2 (0.64) MMP2MMP3MMP1MMP9MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP claimed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1181017-A1 METALLOPROTEASE INHIBITORS Pfizer Limited (GB) 2002-02-27 EP disclosed
WO-2000074681-A1 METALLOPROTEASE INHIBITORS PFIZER LIMITED (GB) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.